Current Rating Overview
MarketsMOJO currently assigns Themis Medicare Ltd a 'Sell' rating, reflecting a cautious stance on the stock. This rating was revised on 06 Apr 2026, when the Mojo Score improved modestly from 26 to 31 points, moving the grade from 'Strong Sell' to 'Sell'. Despite this improvement, the recommendation indicates that investors should remain wary of the stock’s near-term prospects given prevailing risks and performance challenges.
Understanding the Rating Parameters
The 'Sell' rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s investment appeal and risk profile.
Quality Assessment
As of 10 May 2026, Themis Medicare’s quality grade is considered average. The company’s long-term growth trajectory has been disappointing, with operating profit shrinking at an annualised rate of -185.54% over the past five years. This steep decline highlights structural challenges in the business model or competitive pressures within the Pharmaceuticals & Biotechnology sector. Additionally, the latest half-year results show a 50.60% contraction in profit after tax (PAT) to ₹7.32 crores and a 20.25% decline in net sales to ₹168.12 crores, signalling subdued operational performance.
Valuation Perspective
The valuation grade is marked as risky, reflecting concerns over the company’s financial health and market pricing. Themis Medicare is currently trading with a negative EBITDA of ₹-9.18 crores, indicating operational losses. Over the past year, the stock has delivered a negative return of -20.39%, while profits have deteriorated by -135.9%. Compared to its historical valuation averages, the stock appears expensive relative to its earnings and cash flow generation, which raises caution for value-conscious investors.
Financial Trend Analysis
The financial trend is flat, underscoring a lack of meaningful improvement in key financial metrics. The company’s return on capital employed (ROCE) for the half year stands at a negative -3.47%, the lowest in recent periods, reflecting inefficient capital utilisation. The flat trend is further evidenced by the absence of growth in recent quarterly results and persistent losses, which dampen confidence in a near-term turnaround.
Technical Outlook
Technically, the stock is mildly bearish. Price movements over the last month have been positive, with a 17.70% gain, and a 15.70% rise over three months, suggesting some short-term momentum. However, the six-month return is negative at -15.93%, and the year-to-date performance shows a decline of -3.19%. The one-year return of -20.81% significantly underperforms the broader market benchmark, the BSE500, which has generated a 5.38% return over the same period. This divergence indicates weak investor sentiment and technical resistance levels that may limit upside potential.
Market Position and Investor Interest
Themis Medicare remains a microcap company within the Pharmaceuticals & Biotechnology sector. Notably, domestic mutual funds hold no stake in the company, which may reflect a lack of confidence or insufficient research coverage by institutional investors. This absence of institutional backing can contribute to lower liquidity and higher volatility, factors that investors should consider when evaluating the stock.
Summary for Investors
In summary, the 'Sell' rating on Themis Medicare Ltd signals that the stock currently carries significant risks related to its financial performance, valuation, and market sentiment. While there has been a slight improvement in the Mojo Score and rating grade, the company’s operational challenges, negative profitability, and underwhelming returns relative to the market suggest that investors should approach with caution. The rating advises a defensive stance, favouring capital preservation over speculative exposure.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Contextualising Stock Returns
Themis Medicare’s stock performance over various time frames illustrates the volatility and challenges faced by the company. As of 10 May 2026, the stock has declined by 20.81% over the past year, a stark contrast to the 5.38% gain recorded by the BSE500 index. This underperformance highlights the stock’s vulnerability to sector-specific headwinds and company-specific issues. Shorter-term gains in the last month and quarter suggest sporadic investor interest, but these have not translated into sustained recovery.
Financial Health and Profitability Concerns
The negative EBITDA and declining PAT underscore the company’s struggle to generate consistent profits. The flat financial trend and negative ROCE indicate that capital is not being effectively deployed to create shareholder value. These factors contribute to the cautious valuation and the 'risky' grade assigned to the stock’s price levels. Investors should be mindful that such financial stress can lead to further price volatility and potential dilution risks if capital raising becomes necessary.
Technical Signals and Market Sentiment
From a technical perspective, the mildly bearish grade reflects a market that is hesitant about the stock’s near-term prospects. Despite some recent positive price movements, the overall trend remains weak, and the stock has not regained its previous highs. This technical backdrop suggests that investors should monitor price action closely and consider risk management strategies if holding the stock.
Investor Takeaway
For investors, the 'Sell' rating on Themis Medicare Ltd serves as a signal to reassess exposure to this stock. The current fundamentals, valuation risks, and technical outlook do not support a bullish stance. While the company operates in a vital sector with potential long-term opportunities, the immediate financial and market challenges warrant caution. Investors seeking stability and growth may prefer to explore alternatives with stronger fundamentals and more favourable technical setups.
Conclusion
In conclusion, Themis Medicare Ltd’s 'Sell' rating by MarketsMOJO, last updated on 06 Apr 2026, reflects a comprehensive evaluation of the company’s current standing as of 10 May 2026. The stock’s average quality, risky valuation, flat financial trend, and mildly bearish technicals collectively justify a cautious investment approach. Investors should carefully weigh these factors against their risk tolerance and portfolio objectives before considering any position in this stock.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
